Tectonic Therapeutic, Inc. (TECX): R&D Expense
$63.49M
Year ended 2025-12-31
$72.19M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $63.49M | +53.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $41.36M | +11.9% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $36.97M | n/c | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $72.19M | -13.1% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $83.11M | -4.7% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $87.24M | +58.7% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $54.97M | +56.6% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $35.09M | +131.0% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $15.19M | n/a | 2019-03-25, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $63.49M | +53.5% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $108.89M | +18.6% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $63.80M | -13.9% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $134.67M | +5.7% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $38.31M | -72.1% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $129.62M | +8.5% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $116.68M | +30.6% |
Compare TECX, CHRS, LXEO, VYGR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗